Vascular endothelial growth factor receptor-3 expression in mycosis fungoides

Ida Holst Pedersen; Andreas Willerslev-Olsen; Claudia Vetter-Kauczok; Thorbjørn Krejsgaard; Britt Lauenborg; Katharina Luise Kopp; Carsten Geisler; Charlotte M Bonefeld; Qian Zhang; Mariusz A Wasik; Sally Dabelsteen; Anders Woetmann Andersen; Jurgen C Becker; Niels Odum

doi:10.3109/10428194.2012.726720

Vascular endothelial growth factor receptor-3 expression in mycosis fungoides

Ida Holst Pedersen, Andreas Willerslev-Olsen, Claudia Vetter-Kauczok, Thorbjørn Krejsgaard, Britt Lauenborg, Katharina Luise Kopp, Carsten Geisler, Charlotte M Bonefeld, Qian Zhang, Mariusz A Wasik, Sally Dabelsteen, Anders Woetmann Andersen, Jurgen C Becker, Niels Odum

18 Citations (Scopus)

Abstract

Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). Immunohistochemistry revealed that in two-thirds of 34 patients, VEGFR-3 was expressed in situ by both tumor and stromal cells irrespective of the disease stage. The natural VEGFR-3 ligand, VEGF-C, partially protected malignant T-cell lines from growth inhibition by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Whereas the malignant T cells did not produce VEGF-C in vitro, its expression was induced during tumor formation in vivo in a xenograft mouse model of MF. In conclusion, malignant and stromal cells express high levels of VEGFR-3 in all stages of MF. Moreover, malignant T cells trigger enhanced VEGF-C expression in fibroblasts, suggesting that cross-talk between tumor and stromal cells plays a role in lymphangiogenesis and possibly disease progression.

Original language	English
Journal	Leukemia and Lymphoma
ISSN	1042-8194
DOIs	https://doi.org/10.3109/10428194.2012.726720
Publication status	Published - Apr 2013

Access to Document

10.3109/10428194.2012.726720

Cite this

Pedersen, I. H., Willerslev-Olsen, A., Vetter-Kauczok, C., Krejsgaard, T., Lauenborg, B., Kopp, K. L., Geisler, C., Bonefeld, C. M., Zhang, Q., Wasik, M. A., Dabelsteen, S., Andersen, A. W., Becker, J. C., & Odum, N. (2013). Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leukemia and Lymphoma. https://doi.org/10.3109/10428194.2012.726720

@article{667239e41bcb4acb93b409a18405df90,

title = "Vascular endothelial growth factor receptor-3 expression in mycosis fungoides",

abstract = "Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). Immunohistochemistry revealed that in two-thirds of 34 patients, VEGFR-3 was expressed in situ by both tumor and stromal cells irrespective of the disease stage. The natural VEGFR-3 ligand, VEGF-C, partially protected malignant T-cell lines from growth inhibition by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Whereas the malignant T cells did not produce VEGF-C in vitro, its expression was induced during tumor formation in vivo in a xenograft mouse model of MF. In conclusion, malignant and stromal cells express high levels of VEGFR-3 in all stages of MF. Moreover, malignant T cells trigger enhanced VEGF-C expression in fibroblasts, suggesting that cross-talk between tumor and stromal cells plays a role in lymphangiogenesis and possibly disease progression.",

author = "Pedersen, {Ida Holst} and Andreas Willerslev-Olsen and Claudia Vetter-Kauczok and Thorbj{\o}rn Krejsgaard and Britt Lauenborg and Kopp, {Katharina Luise} and Carsten Geisler and Bonefeld, {Charlotte M} and Qian Zhang and Wasik, {Mariusz A} and Sally Dabelsteen and Andersen, {Anders Woetmann} and Becker, {Jurgen C} and Niels Odum",

year = "2013",

month = apr,

doi = "10.3109/10428194.2012.726720",

language = "English",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

}

TY - JOUR

T1 - Vascular endothelial growth factor receptor-3 expression in mycosis fungoides

AU - Pedersen, Ida Holst

AU - Willerslev-Olsen, Andreas

AU - Vetter-Kauczok, Claudia

AU - Krejsgaard, Thorbjørn

AU - Lauenborg, Britt

AU - Kopp, Katharina Luise

AU - Geisler, Carsten

AU - Bonefeld, Charlotte M

AU - Zhang, Qian

AU - Wasik, Mariusz A

AU - Dabelsteen, Sally

AU - Andersen, Anders Woetmann

AU - Becker, Jurgen C

AU - Odum, Niels

PY - 2013/4

Y1 - 2013/4

N2 - Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). Immunohistochemistry revealed that in two-thirds of 34 patients, VEGFR-3 was expressed in situ by both tumor and stromal cells irrespective of the disease stage. The natural VEGFR-3 ligand, VEGF-C, partially protected malignant T-cell lines from growth inhibition by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Whereas the malignant T cells did not produce VEGF-C in vitro, its expression was induced during tumor formation in vivo in a xenograft mouse model of MF. In conclusion, malignant and stromal cells express high levels of VEGFR-3 in all stages of MF. Moreover, malignant T cells trigger enhanced VEGF-C expression in fibroblasts, suggesting that cross-talk between tumor and stromal cells plays a role in lymphangiogenesis and possibly disease progression.

AB - Here, we have studied vascular endothelial growth factor receptor-3 (VEGFR-3) expression in mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). Immunohistochemistry revealed that in two-thirds of 34 patients, VEGFR-3 was expressed in situ by both tumor and stromal cells irrespective of the disease stage. The natural VEGFR-3 ligand, VEGF-C, partially protected malignant T-cell lines from growth inhibition by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Whereas the malignant T cells did not produce VEGF-C in vitro, its expression was induced during tumor formation in vivo in a xenograft mouse model of MF. In conclusion, malignant and stromal cells express high levels of VEGFR-3 in all stages of MF. Moreover, malignant T cells trigger enhanced VEGF-C expression in fibroblasts, suggesting that cross-talk between tumor and stromal cells plays a role in lymphangiogenesis and possibly disease progression.

U2 - 10.3109/10428194.2012.726720

DO - 10.3109/10428194.2012.726720

M3 - Journal article

C2 - 22946664

SN - 1042-8194

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Vascular endothelial growth factor receptor-3 expression in mycosis fungoides

Abstract

Access to Document

Fingerprint

Cite this